R&D

HDD

Hyaluronic Acid Conjugated Drugs, HACD

We have developed a “targeting” treatment based on the fact that hyaluronic acid specifically combines with cell surface receptors, glycoprotein CD44 (cluster of differentiation 44) and RHAMM (receptor for hyaluronan mediated motility), which are highly expressed in certain cancer cells. We then select anti-cancer drugs, and conjugate them with hyaluronic acid. Using hyaluronic acid as a carrier, we develop hyaluronic acid conjugated drugs targeted to cancer cells.
*
We are developing a new HACD drug, CA102N. By conjugating an existing chemotherapy drug with hyaluronic acid, since colorectal cancer cells have higher expression levels of the CD44 receptor, we are able to ensure a high specificity in the delivery of drug to tumor. This novel receptor targeted chemotherapy drug is designed for colorectal cancer treatment. We are expecting higher efficacy, lower side effects and also a reduction in the dosage compared to traditional chemotherapy drugs. previous page